UK Approves Daily Pill for Weight Loss: Wegovy Shows Significant Results

The United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) has approved the first daily pill for weight loss, Wegovy, containing the active ingredient semaglutide. This marks a significant expansion in treatment options for individuals struggling with obesity and weight management.

Wegovy is intended for daily use by adults classified as obese (BMI of 30 or higher) or overweight with associated health issues, such as high blood pressure. The approval comes as a supplement to a reduced-calorie diet and increased physical activity, aiming to provide a sustainable approach to weight reduction.

“

As it has met MHRA’s stringent standards for safety, quality, and effectiveness, the semaglutide tablet has been approved in the UK for weight loss and weight management. Like all GLP-1 receptor agonists, it is a prescription-only medicine.

Clinical trial data presented to the MHRA demonstrated the drug's efficacy. Participants taking the 25-milligram daily dose, alongside diet and exercise, achieved an average weight loss of 17% over 64 weeks. When considering all participants, regardless of continued treatment, the average weight loss was 14%.

The medication works by mimicking the GLP-1 hormone, which regulates appetite. Semaglutide affects appetite-regulating centers in the brain, promoting a longer feeling of fullness and reducing cravings. While approved for prescription use, its availability within the UK's National Health Service (NHS) is still under evaluation. Common side effects reported include digestive issues like nausea, diarrhea, constipation, and vomiting.

“

This is an important milestone in the treatment of obesity.